Published in Lab Business Week, January 23rd, 2005
Including the sale of these additional shares, Array completed the offering for 9,200,000 shares of common stock at $7.75 per share, resulting in net proceeds of approximately $67 million.
Array anticipates using the net proceeds from this offering to fund research and development efforts, including clinical trials for its proprietary candidates; and for general corporate purposes, including working capital.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week